Current pharmacological treatments for tinnitus

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 17, 2012, Pages 2495-2509

  Langguth, Berthold ^a   Elgoyhen, Ana Belén ^b,c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b INSTITUTO DE INVESTIGACIONES EN INGENIERÍA GENÉTICA Y BIOLOGÍA MOLECULAR   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Auditory system; Hearing; Meta analysis; Pharmacotherapy; Randomized controlled trial; Systematic review; Tinnitus; Treatment

Indexed keywords

ACAMPROSATE; ALPRAZOLAM; AMITRIPTYLINE; ATORVASTATIN; BACLOFEN; CARBAMAZEPINE; CAROVERINE; CLONAZEPAM; CYCLANDELATE; CYCLOBENZAPRINE; DIAZEPAM; FLECAINIDE; FLUOXETINE; FUROSEMIDE; GABAPENTIN; LAMOTRIGINE; LIDOCAINE; MEMANTINE; MEXILETINE; MISOPROSTOL; NIMODIPINE; NORTRIPTYLINE; PAROXETINE; PREGABALIN; SERTRALINE; SULPIRIDE; TOCAINIDE; TRIMIPRAMINE; UNINDEXED DRUG; VALPROIC ACID;

ACUTE TINNITUS; ANIMAL MODEL; ANXIETY DISORDER; AUDITORY STIMULATION; CHRONIC TINNITUS; CLINICAL RESEARCH; COCHLEA PROSTHESIS; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROSTIMULATION; EXPERIMENTAL THERAPY; FEEDBACK SYSTEM; HEALTH CARE COST; HEARING TEST; HUMAN; INSOMNIA; NONHUMAN; OFF LABEL DRUG USE; PATHOPHYSIOLOGY; PATIENT COUNSELING; PREVALENCE; REVIEW; SOUND THERAPY; TINNITUS; TRANSCRANIAL MAGNETIC STIMULATION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; TINNITUS;

EID: 84869744891     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.739608     Document Type: Review

References (172)

1. Shargorodsky J, Curhan GC, Farwell WR. Prevalence and characteristics of tinnitus among US adults. AmJ Med 2010;123:711-18
2. Axelsson A, Ringdahl A. Tinnitus-a study of its prevalence and characteristics. Br J Audiol 1989;23:53-62
3. Krog NH, Engdahl B, Tambs K. The association between tinnitus and mental health in a general population sample: results from the HUNT Study. J Psychosom Res 2010;69:289-98
4. Lasisi AO, Abiona T, Gureje O. Tinnitus in the elderly: profile, correlates, and impact in the Nigerian Study of Ageing. Otolaryngol Head Neck Surg 2010;143:510-15
5. Michikawa T, Nishiwaki Y, Kikuchi Y, et al. Prevalence and factors associated with tinnitus: a community-based study of Japanese elders. J Epidemiol 2010;20:271-6
6. Khedr EM, Ahmed MA, Shawky OA, et al. Epidemiological study of chronic tinnitus in assiut, Egypt. Neuroepidemiology 2010;35:45-52
7. Langguth B. A review of tinnitus symptoms beyond 'ringing in the ears': a call to action. Curr Med Res Opin 2011;27:1635-43
8. Vio MM, Holme RH. Hearing loss and tinnitus: 250 million people and a US $10 billion potential market. Drug Discov Today 2005;10:1263-5
9. Lobarinas E, Sun W, Stolzberg D, et al. Human brain imaging of tinnitus and animal models. Semin Hear 2008;29:333-49
10. Norena AJ. An integrative model of tinnitus based on a central gain controlling neural sensitivity. Neurosci Biobehav Rev 2011;35:1089-109
11. Eggermont JJ, Roberts LE. The neuroscience of tinnitus. Trends Neurosci 2004;27:676-82
12. Yang S, Weiner BD, Zhang LS, et al. Homeostatic plasticity drives tinnitus perception in an animal model. Proc Natl Acad Sci USA 2011;108:14974-9
13. Richardson BD, Brozoski TJ, Ling LL, Caspary DM. Targeting inhibitory neurotransmission in tinnitus. Brain Res 2012; in press 14. Brozoski T, Odintsov B, Bauer C. Gamma-aminobutyric acid and glutamic acid levels in the auditory pathway of rats with chronic tinnitus: a direct determination using high resolution point-resolved proton magnetic resonance spectroscopy (H-MRS). Front Syst Neurosci 2012;6:9
14. Rauschecker JP, Leaver AM, Muhlau M. Tuning out the noise: limbic-auditory interactions in tinnitus. Neuron 2010;66:819-26
15. Simpson JJ, Davies WE. A review of evidence in support of a role for 5-HT in the perception of tinnitus. Hear Res 2000;145:1-7
16. Caperton KK, Thompson AM. Activation of serotonergic neurons during salicylate-induced tinnitus. Laryngoscope 2010;120(Suppl 4):S203
17. Roberts LE, Eggermont JJ, Caspary DM, et al. Ringing ears: the neuroscience of tinnitus. J Neurosci 2010;30:14972-9
18. Vielsmeier V, Strutz J, Kleinjung T, et al. Temporomandibular joint disorder complaints in tinnitus: further hints for a putative tinnitus subtype. PLoS One 2012;7:e38887
19. Llinas RR, Ribary U, Jeanmonod D, et al. Thalamocortical dysrhythmia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography. Proc Natl Acad Sci USA 1999;96:15222-7
20. De Ridder D, Elgoyhen AB, Romo R, Langguth B. Phantom percepts: tinnitus and pain as persisting aversive memory networks. Proc Natl Acad Sci USA 2011;108:8075-80
21. Schlee W, Hartmann T, Langguth B, Weisz N. Abnormal resting-state cortical coupling in chronic tinnitus. BMC Neurosci 2009;10:11
22. Vanneste S, Plazier M, van der Loo E, et al. The neural correlates of tinnitus-related distress. Neuroimage 2010;52:470-80
23. De Ridder D, Fransen H, Francois O, et al. Amygdalohippocampal involvement in tinnitus and auditory memory. Acta Otolaryngol Suppl 2006(556):50-3
24. Eggermont JJ. Hearing loss, hyperacusis, or tinnitus: What is modeled in animal research? Hear Res 2012; in press 27. Adamchic I, Langguth B, Hauptmann C, Tass PA. Psychometric evaluation of Visual Analog Scale for the assessment of chronic tinnitus. Am J Audiol 2012; in press 28. Zeman F, Koller M, Figueiredo R, et al. Tinnitus handicap inventory for evaluating treatment effects: which changes are clinically relevant? Otolaryngol Head Neck Surg 2011
25. Adamchic I, Tass PA, Langguth B, et al. Linking the Tinnitus Questionnaire and the subjective Clinical Global Impression: which differences are clinically important? Health Qual Life Outcomes 2012;10:79
26. Meikle MB, Henry JA, Griest SE, et al. The tinnitus functional index: development of a new clinical measure for chronic, intrusive tinnitus. Ear Hear 2012;32:153-76
27. Langguth B, Goodey R, Azevedo A, et al. Consensus for tinnitus patient assessment and treatment outcome measurement: tinnitus Research Initiative meeting, Regensburg, July 2006. Prog Brain Res 2007;166:525-36
28. Landgrebe M, Azevedo A, Baguley D, et al. Methodological aspects of clinical trials in tinnitus: a proposal for an international standard. J Psychosom Res 2012;73:112-21
29. Vanneste S, De Ridder D. The auditory and non-auditory brain areas involved in tinnitus. an emergent property of multiple parallel overlapping subnetworks. Front Syst Neurosci 2012;6:31
30. Schlee W, Kleinjung T, Hiller W, et al. Does tinnitus distress depend on age of onset? PLoS One 2011;6:e27379
31. Mardini MK. Ear-clicking "tinnitus" responding to carbamazepine. N Engl J Med 1987;317:1542
32. Landgrebe M, Zeman F, Koller M, et al. The Tinnitus Research Initiative (TRI) database: a new approach for delineation of tinnitus subtypes and generation of predictors for treatment outcome. BMC Med Inform Decis Mak 2010;10:42
33. Tyler R, Coelho C, Tao P, et al. Identifying tinnitus subgroups with cluster analysis. Am J Audiol 2008;17:S176-84
34. Schecklmann M, Lehner A, Poeppl TB, et al. Cluster analysis for identifying sub-types of tinnitus: a positron emission tomography and voxel-based morphometry study. Brain Res 2012; in press
35. Cima RF, Maes IH, Joore MA, et al. Specialised treatment based on cognitive behaviour therapy versus usual care for tinnitus: a randomised controlled trial. Lancet 2012;379:1951-9
36. Martinez-Devesa P, Perera R, Theodoulou M, Waddell A. Cognitive behavioural therapy for tinnitus. Cochrane Database Syst Rev 2010;CD005233
37. Hobson J, Chisholm E, El Refaie A. Sound therapy (masking) in the management of tinnitus in adults. Cochrane Database Syst Rev 2010;CD006371
38. Schaette R, Konig O, Hornig D, et al. Acoustic stimulation treatments against tinnitus could be most effective when tinnitus pitch is within the stimulated frequency range. Hear Res 2010;269:95-101
39. Phillips JS, McFerran D. Tinnitus Retraining Therapy (TRT) for tinnitus. Cochrane Database Syst Rev 2010;CD007330
40. Tyler RS. Patient preferences and willingness to pay for tinnitus treatments. J Am Acad Audiol 2012;23:115-25
41. Hall DA, Lainez MJ, Newman CW, et al. Treatment options for subjective tinnitus: self reports from a sample of general practitioners and ENT physicians within Europe and the USA. BMC Health Serv Res 2011;11:302
42. Langguth B. Tinnitus: the end of therapeutic nihilism. Lancet 2012;379:1926-8
43. Dolgin E. Sound medicine. Nat Med 2012;18:642-5
44. Hoare DJ, Kowalkowski VL, Kang S, Hall DA. Systematic review and meta-analyses of randomized controlled trials examining tinnitus management. Laryngoscope 2011;121:1555-64
45. Dobie RA. A review of randomized clinical trials in tinnitus. Laryngoscope 1999;109:1202-11
46. Hesser H. Methodological considerations in treatment evaluations of tinnitus distress: a call for guidelines. J Psychosom Res 2010;69:305-7
47. Bennett MH, Kertesz T, Yeung P. Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus. Cochrane Database Syst Rev 2007;CD004739
48. Baldo P, Doree C, Lazzarini R, et al. Antidepressants for patients with tinnitus. Cochrane Database Syst Rev 2006;CD00385
49. Hilton M, Stuart E. Ginkgo biloba for tinnitus. Cochrane Database Syst Rev 2004;CD003852
50. Hoekstra CE, Rynja SP, van Zanten GA, Rovers MM. Anticonvulsants for tinnitus. Cochrane Database Syst Rev 2011;CD007960
51. Melding PS, Goodey RJ, Thorne PR. The use of intravenous lignocaine in the diagnosis and treatment of tinnitus. J Laryngol Otol 1978;92:115-21
52. Trellakis S, Lautermann J, Lehnerdt G. Lidocaine: neurobiological targets and effects on the auditory system. Prog Brain Res 2007;166:303-22
53. Gil-Gouveia R, Goadsby PJ. Neuropsychiatric side-effects of lidocaine: examples from the treatment of headache and a review. Cephalalgia 2009;29:496-508
54. Darlington CL, Smith PF. Drug treatments for tinnitus. Prog Brain Res 2007;166:249-62
55. Savastano M. Lidocaine intradermal injection-a new approach in tinnitus therapy: preliminary report. Adv Ther 2004;21:13-20
56. Slattery WH, Fisher LM, Iqbal Z, et al. Intratympanic steroid injection for treatment of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg 2005;133:251-9
57. Slattery WH, Fisher LM, Iqbal Z, Liu N. Oral steroid regimens for idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2005;132:5-10
58. Shim HJ, Song SJ, Choi AY, et al. Comparison of various treatment modalities for acute tinnitus. Laryngoscope 2011;121:2619-25
59. Narozny W, Kuczkowski J, Kot J, et al. Prognostic factors in sudden sensorineural hearing loss: our experience and a review of the literature. Ann Otol Rhinol Laryngol 2006;115:553-8
60. Stokroos RJ, Albers FW, Tenvergert EM. Antiviral treatment of idiopathic sudden sensorineural hearing loss: a prospective, randomized, double-blind clinical trial. Acta Otolaryngol 1998;118:488-95
61. Westerlaken BO, Stokroos RJ, Dhooge IJ, et al. Treatment of idiopathic sudden sensorineural hearing loss with antiviral therapy: a prospective, randomized, double-blind clinical trial. Ann Otol Rhinol Laryngol 2003;112:993-1000
62. Hu A, Parnes LS. Intratympanic steroids for inner ear disorders: a review. Audiol Neurootol 2009;14:373-82
63. Spear SA, Schwartz SR. Intratympanic steroids for sudden sensorineural hearing loss: a systematic review. Otolaryngol Head Neck Surg 2011;145:534-43
64. Lim DJ. Effects of noise and ototoxic drugs at the cellular level in the cochlea: a review. Am J Otolaryngol 1986;7:73-99
65. Puel JL, Ruel J, Guitton M, Pujol R. The inner hair cell afferent/efferent synapses revisited: a basis for new therapeutic strategies. Adv Otorhinolaryngol 2002;59:124-30
66. Holley MC. Keynote review: the auditory system, hearing loss and potential targets for drug development. Drug Discov Today 2005;10:1269-82
67. Lynch ED, Kil J. Compounds for the prevention and treatment of noise-induced hearing loss. Drug Discov Today 2005;10:1291-8
68. Attias J, Weisz G, Almog S, et al. Oral magnesium intake reduces permanent hearing loss induced by noise exposure. Am J Otolaryngol 1994;15:26-32
69. Lin CY, Wu JL, Shih TS, et al. N-Acetyl-cysteine against noise-induced temporary threshold shift in male workers. Hear Res 2010;269:42-7
70. Kramer S, Dreisbach L, Lockwood J, et al. Efficacy of the antioxidant N-acetylcysteine (NAC) in protecting ears exposed to loud music. J Am Acad Audiol 2006;17:265-78
71. Kopke RD, Jackson RL, Coleman JK, et al. NAC for noise: from the bench top to the clinic. Hear Res 2007;226:114-25
72. Ewert DL, Lu J, Li W, et al. Antioxidant treatment reduces blast-induced cochlear damage and hearing loss. Hear Res 2012;285:29-39
73. Ebselen in College Students. Available from: (http://clinicaltrials.gov/ ct2/show/NCT01444846?term=ebselen&rank=1) 2012
74. Ebselen in Chemotherapy induced hearing loss. Available from: http://clinicaltrials.gov/ct2/show/NCT01451853?term=ebselen&rank=2 2012
75. Muehlmeier G, Biesinger E, Maier H. Safety of intratympanic injection of AM-101 in patients with acute inner ear tinnitus. Audiol Neurootol 2011;16:388-97
76. Van de Heyning P, Cox T, Maier H, et al. Efficacy and safety of AM-101 in the treatment of acute inner ear tinnitus - a double blind, randomised, placebo controlled phase II study [abstract]. Abstract Book of the 6th TRI Meeting 2012. 6:19
77. Robinson SK, Viirre ES, Stein MB. Antidepressant therapy in tinnitus. Hear Res 2007;226:221-31
78. Langguth B, Landgrebe M, Kleinjung T, et al. Tinnitus and depression. World J Biol Psychiatry 2011;12:489-500
79. Tonndorf J. The analogy between tinnitus and pain: a suggestion for a physiological basis of chronic tinnitus. Hear Res 1987;28:271-5
80. Mico JA, Ardid D, Berrocoso E, Eschalier A. Antidepressants and pain. Trends Pharmacol Sci 2006;27:348-54
81. Sullivan MD, Dobie RA, Sakai CS, Katon WJ. Treatment of depressed tinnitus patients with nortriptyline. Ann Otol Rhinol Laryngol 1989;98:867-72
82. Sullivan M, Katon W, Russo J, et al. A randomized trial of nortriptyline for severe chronic tinnitus. Effects on depression, disability, and tinnitus symptoms. Arch Intern Med 1993;153:2251-9
83. Katon W, Sullivan M, Russo J, et al. Depressive symptoms and measures of disability: a prospective study. J Affect Disord 1993;27:245-54
84. Bayar N, Boke B, Turan E, Belgin E. Efficacy of amitriptyline in the treatment of subjective tinnitus. J Otolaryngol 2001;30:300-3
85. Podoshin L, Ben-David Y, Fradis M, et al. Idiopathic subjective tinnitus treated by amitriptyline hydrochloride/biofeedback. Int Tinnitus J 1995;1:54-60
86. Mihail RC, Crowley JM, Walden BE, et al. The tricyclic trimipramine in the treatment of subjective tinnitus. Ann Otol Rhinol Laryngol 1988;97:120-3
87. Feder R. Tinnitus associated with amitriptyline. J Clin Psychiatry 1990;51:85-6
88. Mendis D, Johnston M. An unusual case of prolonged tinnitus following low-dose amitriptyline. J Psychopharmacol 2008;22:574-5
89. Tandon R, Grunhaus L, Greden JF. Imipramine and tinnitus. J Clin Psychiatry 1987;48:109-11
90. Langguth B, Landgrebe M, Wittmann M, et al. Persistent tinnitus induced by tricyclic antidepressants. J Psychopharmacol 2010;24:1273-5
91. Clewes J. A case report of onset of tinnitus following discontinuation of antidepressant and a review of the literature. Prim Care Companion CNS Disord 2012;14
92. Zoger S, Svedlund J, Holgers KM. The effects of sertraline on severe tinnitus suffering-a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2006;26:32-9
93. Robinson SK, Viirre ES, Bailey KA, et al. Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosom Med 2005;67:981-8
94. Roberts C, Inamdar A, Koch A, et al. A randomized, controlled study comparing the effects of vestipitant or vestipitant and paroxetine combination in subjects with tinnitus. Otol Neurotol 2011;32:721-7
95. Langguth B, Kleinjung T, Fischer B, et al. Tinnitus severity, depression, and the big five personality traits. Prog Brain Res 2007;166:221-5
96. Johnson RM, Brummett R, Schleuning A. Use of alprazolam for relief of tinnitus. A double-blind study. Arch Otolaryngol Head Neck Surg 1993;119:842-5
97. Jalali MM, Kousha A, Naghavi SE, et al. The effects of alprazolam on tinnitus: a cross-over randomized clinical trial. Med Sci Monit 2009;15:I55-60
98. Kay NJ. Oral chemotherapy in tinnitus. Br J Audiol 1981;15:123-4
99. Bahmad FM Jr, Venosa AR, Oliveira CA. Benzodiazepines and GABAergics in treating severe disabling tinnitus of predominantly cochlear origin. Int Tinnitus J 2006;12:140-4
100. Gananca MM, Caovilla HH, Gananca FF, et al. Clonazepam in the pharmacological treatment of vertigo and tinnitus. Int Tinnitus J 2002;8:50-3
101. Han SS, Nam EC, Won JY, et al. Clonazepam Quiets tinnitus: a randomised crossover study with Ginkgo Biloba. J Neurol Neurosurg Psychiatry 2012;83:821-7
102. Busto U, Fornazzari L, Naranjo CA. Protracted tinnitus after discontinuation of long-term therapeutic use of benzodiazepines. J Clin Psychopharmacol 1988;8:359-62
103. Busto U, Sellers EM, Naranjo CA, et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986;315:854-9
104. Eggermont JJ. Tinnitus: neurobiological substrates. Drug Discov Today 2005;10:1283-90
105. Melding PS, Goodey RJ. The treatment of tinnitus with oral anticonvulsants. J Laryngol Otol 1979;93:111-22
106. Sanchez TG, Balbani AP, Bittar RS, et al. Lidocaine test in patients with tinnitus: rationale of accomplishment and relation to the treatment with carbamazepine. Auris Nasus Larynx 1999;26:411-17
107. Shea JJ, Harell M. Management of tinnitus aurium with lidocaine and carbamazepine. Laryngoscope 1978;88:1477-84
108. Donaldson I. Tegretol: a double blind trial in tinnitus. J Laryngol Otol 1981;95:947-51
109. Hulshof JH, Vermeij P. The value of carbamazepine in the treatment of tinnitus. ORL J Otorhinolaryngol Relat Spec 1985;47:262-6
110. Levine RA. Typewriter tinnitus: a carbamazepine-responsive syndrome related to auditory nerve vascular compression. ORL J Otorhinolaryngol Relat Spec 2006;68:43-6
111. Bauer CA, Brozoski TJ. Effect of gabapentin on the sensation and impact of tinnitus. Laryngoscope 2006;116:675-81
112. Witsell DL, Hannley MT, Stinnet S, Tucci DL. Treatment of tinnitus with gabapentin: a pilot study. Otol Neurotol 2007;28:11-15
113. Bakhshaee M, Ghasemi M, Azarpazhooh M, et al. Gabapentin effectiveness on the sensation of subjective idiopathic tinnitus: a pilot study. Eur Arch Otorhinolaryngol 2008;265:525-30
114. Piccirillo JF, Finnell J, Vlahiotis A, et al. Relief of idiopathic subjective tinnitus: is gabapentin effective? Arch Otolaryngol Head Neck Surg 2007;133:390-7
115. Dehkordi MA, Abolbashari S, Taheri R, Einolghozati S. Efficacy of gabapentin on subjective idiopathic tinnitus: a randomized, double-blind, placebo-controlled trial. Ear Nose Throat J 2011;90:150-8
116. Aazh H, El RA, Humphriss R. Gabapentin for tinnitus: a systematic review. Am J Audiol 2011;20:151-8
117. Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin a meta-analysis of randomized controlled trials. Pain 2009;145:69-81
118. Montgomery SA, Herman BK, Schweizer E, Mandel FS. The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. Int Clin Psychopharmacol 2009;24:214-22
119. Russell IJ, Crofford LJ, Leon T, et al. The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Med 2009;10:604-10
120. Simpson JJ, Gilbert AM, Weiner GM, Davies WE. The assessment of lamotrigine, an antiepileptic drug, in the treatment of tinnitus. Am J Otol 1999;20:627-31
121. Mansbach AL, Freyens P. Tinnitus: current data and treatment with sodium valproate. Acta Otorhinolaryngol Belg 1983;37:697-705
122. Menkes DB, Larson PM. Sodium valproate for tinnitus. J Neurol Neurosurg Psychiatry 1998;65:803
123. Guitton MJ, Wang J, Puel JL. New pharmacological strategies to restore hearing and treat tinnitus. Acta Otolaryngol 2004;124:411-15
124. Denk DM, Heinzl H, Franz P, Ehrenberger K. Caroverine in tinnitus treatment. A placebo-controlled blind study. Acta Otolaryngol 1997;117:825-30
125. Domeisen H, Hotz MA, Hausler R. Caroverine in tinnitus treatment. Acta Otolaryngol 1998;118:606-8
126. Ehrenberger K. Topical administration of Caroverine in somatic tinnitus treatment: proof-of-concept study. Int Tinnitus J 2005;11:34-7
127. Azevedo AA, Figueiredo RR. Treatment of tinnitus with acamprosate. Prog Brain Res 2007;166:273-7
128. Sharma DK, Kaur S, Singh J, Kaur I. Role of acamprosate in sensorineural tinnitus. Indian J Pharmacol 2012;44:93-6
129. Accamprosate. Available from: http://clinicaltrials.gov/ct2/show/ NCT00596531 2012
130. Figueiredo RR, Langguth B, Mello de OP, de Azevedo AA. Tinnitus treatment with memantine. Otolaryngol Head Neck Surg 2008;138:492-6
131. Plazas PV, Savino J, Kracun S, et al. Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-Daspartate receptors. Eur J Pharmacol 2007;566:11-19
132. Suckfuell M, Althaus M, Ellers-Lenz B, et al. A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus. BMC Ear Nose Throat Disord 2011;11:1
133. Neramexane: Clin Trial. Availables from http://clinicaltrials.gov/ct2/ show/NCT00739635, http://clinicaltrials.gov/ct2/show/NCT00772980, http://clinicaltrials.gov/ct2/show/NCT00827008 2011
134. Lopez-Gonzalez MA, Santiago AM, Esteban-Ortega F. Sulpiride and melatonin decrease tinnitus perception modulating the auditolimbic dopaminergic pathway. J Otolaryngol 2007;36:213-19
135. Lopez-Gonzalez MA, Moliner-Peiro F, Faro-Garcia J, Esteban-Ortega F. Sulpiride plus hydroxyzine decrease tinnitus perception. Auris Nasus Larynx 2007;34:23-7
136. de Azevedo AA, Langguth B, de Oliveira PM, Rodrigues FR. Tinnitus treatment with piribedil guided by electrocochleography and acoustic otoemissions. Otol Neurotol 2009;30:676-80
137. Sziklai I, Szilvassy J, Szilvassy Z. Tinnitus control by dopamine agonist pramipexole in presbycusis patients: a randomized, placebo-controlled, double-blind study. Laryngoscope 2011;121:888-93
138. Szczepaniak WS, Moller AR. Effects of (-)-baclofen, clonazepam, and diazepam on tone exposure-induced hyperexcitability of the inferior colliculus in the rat: possible therapeutic implications for pharmacological management of tinnitus and hyperacusis. Hear Res 1996;97:46-53
139. Westerberg BD, Roberson JB Jr, Stach BA. A double-blind placebocontrolled trial of baclofen in the treatment of tinnitus. Am J Otol 1996;17:896-903
140. Zheng Y, Vagal S, McNamara E, et al. A dose-response analysis of the effects of L-baclofen on chronic tinnitus caused by acoustic trauma in rats. Neuropharmacology 2012;62:940-6
141. Smith PF, Zheng Y, Darlington CL. Revisiting baclofen for the treatment of severe chronic tinnitus. Front Neurol 2012;3:34
142. Coelho C, Figueiredo R, Frank E, et al. Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: an open-label pilot study. Audiol Neurootol 2012;17:179-88
143. Vanneste S, Figueiredo R, De Ridder D. Treatment of tinnitus with cyclobenzaprine: an open-label study. Int J Clin Pharmacol Ther 2012;50:338-44
144. Olzowy B, Canis M, Hempel JM, et al. Effect of atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: results of a prospective, randomized, double-blind clinical trial. Otol Neurotol 2007;28:455-8
145. Memin Y. Perceived efficacy of cyclandelate in the treatment of cochleovestibular and retinal disturbances related to cerebrovascular insufficiency. A study in general practice comprising 2772 patients. Drugs 1987;33(Suppl 2):120-4
146. Hester TO, Theilman G, Green W, Jones RO. Cyclandelate in the management of tinnitus: a randomized, placebo-controlled study. Otolaryngol Head Neck Surg 1998;118:329-32
147. Risey JA, Guth PS, Amedee RG. Furosemide distinguishes central and peripheral tinnitus. Int Tinnitus J 1995;1:99-103
148. Drew S, Davies E. Effectiveness of Ginkgo biloba in treating tinnitus: double blind, placebo controlled trial. BMJ 2001;322:73
149. Rejali D, Sivakumar A, Balaji N. Ginkgo biloba does not benefit patients with tinnitus: a randomized placebo-controlled double-blind trial and meta-analysis of randomized trials. Clin Otolaryngol Allied Sci 2004;29:226-31
150. Rosenberg SI, Silverstein H, Rowan PT, Olds MJ. Effect of melatonin on tinnitus. Laryngoscope 1998;108:305-10
151. Yilmaz I, Akkuzu B, Cakmak O, Ozluoglu LN. Misoprostol in the treatment of tinnitus: a double-blind study. Otolaryngol Head Neck Surg 2004;130:604-10
152. Davies E, Knox E, Donaldson I. The usefulness of nimodipine, an L-calcium channel antagonist, in the treatment of tinnitus. Br J Audiol 1994;28:125-9
153. Mazurek B, Haupt H, Szczepek AJ, et al. Evaluation of vardenafil for the treatment of subjective tinnitus: a controlled pilot study. J Negat Results Biomed 2009;8:3
154. Yetiser S, Tosun F, Satar B, et al. The role of zinc in management of tinnitus. Auris Nasus Larynx 2002;29:329-33
155. Coelho CB, Tyler R, Hansen M. Zinc as a possible treatment for tinnitus. Prog Brain Res 2007;166:279-85
156. Howland RH. Serendipity and psychopharmacology. J Psychosoc Nurs Ment Health Serv 2010;48:9-12
157. Jastreboff PJ, Brennan JF, Coleman JK, Sasaki CT. Phantom auditory sensation in rats: an animal model for tinnitus. Behav Neurosci 1988;102:811-22
158. Jastreboff PJ, Brennan JF, Sasaki CT. Quinine-induced tinnitus in rats. Arch Otolaryngol Head Neck Surg 1991;117:1162-6
159. Lobarinas E, Sun W, Cushing R, Salvi R. A novel behavioral paradigm for assessing tinnitus using schedule-induced polydipsia avoidance conditioning (SIPAC). Hear Res 2004;190:109-14
160. Bauer CA, Brozoski TJ. Assessing tinnitus and prospective tinnitus therapeutics using a psychophysical animal model. J Assoc Res Otolaryngol 2001;2:54-64
161. Ruttiger L, Ciuffani J, Zenner HP, Knipper M. A behavioral paradigm to judge acute sodium salicylate-induced sound experience in rats: a new approach for an animal model on tinnitus. Hear Res 2003;180:39-50
162. Guitton MJ, Caston J, Ruel J, et al. Salicylate induces tinnitus through activation of cochlear NMDA receptors. J Neurosci 2003;23:3944-52
163. Leaver AM, Renier L, Chevillet MA, et al. Dysregulation of limbic and auditory networks in tinnitus. Neuron 2011;69:33-43
164. Gulledge AT, Stuart GJ. Excitatory actions of GABA in the cortex. Neuron 2003;37:299-309
165. Kaufmann SH. Paul Ehrlich: founder of chemotherapy. Nat Rev Drug Discov 2008;7:373
166. Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370
167. Elgoyhen AB, Langguth B, Vanneste S, De RD. Tinnitus: Network pathophysiology-network pharmacology. Front Syst Neurosci 2012;6:1
168. Meeus O, De RD, Van de HP. Administration of the combination clonazepam-Deanxit as treatment for tinnitus. Otol Neurotol 2011;32:701-9
169. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4:682-90
170. Azmi AS, Wang Z, Philip PA, et al. Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol Cancer Ther 2010;9:3137-44
171. Yildirim MA, Goh KI, Cusick ME, et al. Drug-target network. Nat Biotechnol 2007;25:1119-26
172. Lounkine E, Keiser MJ, Whitebread S, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012;486:361-7